Enlivex Reports 79% Response Rate With Allocetra In Older Knee OA Patients

Enlivex (ENLV) reported 12-month Phase IIa trial results showing 79.2% of older knee OA patients receiving Allocetra saw pain reduction and function improvement, vs. 47.6% on placebo. The trial had 134 patients, with no serious adverse events. ENLV plans to present findings at ACR Convergence 2026 and expects Phase IIb results by Q2 2027. ENLV stock is down 15.38% at $1.54.

Original reporting
Published Nov 2, 2026, 4:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 2, 2026, 7:31 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefTechnology
Primary signal
$ENLV
Bullish
high confidence
Mentioned
$ENLV
Relevance
8/10
AlphAI data visualization · based on rttnews.com
Decision brief

The 30-second read

$ENLVBullishMed
01

Why it matters

The data provides a catalyst for ENLV, likely prompting short‑term buying interest and a price uptick.

02

Market read

First‑report clinical trial results for a small‑cap biotech, offering a clear trading trigger.

03

What to watch

Potential competition from other OA therapies and the need for larger, longer trials could temper upside.

Relevance 8/10Novelty 8/10Timing: today

Background

Enlivex Therapeutics (ENLV) is a biotech focused on age‑related inflammatory conditions. The Phase IIa trial of its cell‑therapy Allocetra in knee osteoarthritis showed statistically significant pain reduction and functional improvement.

Company-level read

Ticker impact

$ENLVBullishHigh confidence
Context

Enlivex Therapeutics reported Phase IIa topline data showing a 79.2% response rate in older knee OA patients, a new primary disclosure.

Expected impact

upward pressure as investors price in the strong efficacy signal.

Evidence & confidence

The trial met its primary endpoint with statistical significance and no serious safety issues, providing material clinical progress for a biotech.

Market effects

Positive OA data may boost sentiment for the broader biotech and musculoskeletal therapeutic sector.

Limited to markets where ENLV trades; no broader regional effect.

Modest, as the result pertains to a niche therapeutic area.

Counterpoint

Skeptics may question the durability of the response and await Phase IIb data before committing.

Key entities

  • Enlivex Therapeutics Ltd.

    Biotech developer of Allocetra.

  • Allocetra

    Cell‑based therapy evaluated for knee osteoarthritis.

Related articles

$ENLVMed

Enlivex Reports Durable 12-Month Response With Allocetra In Knee Osteoarthritis Trial

Enlivex (ENLV) reported 12-month Phase I/IIa trial results for Allocetra, showing 79.2% of older patients with knee osteoarthritis experienced reduced pain and improved function vs. 47.6% with placebo. The therapy demonstrated a favorable safety profile. The company plans to present findings at ACR Convergence 2026 and expects Phase IIb trial data by Q2 2027. ENLV stock closed at $1.15, up 2.68%.

$ENLVMedAI 8/10

Enlivex's Allocetra Secures FDA RMAT Designation For Knee Osteoarthritis Treatment

Enlivex Ltd. (ENLV) said the FDA granted RMAT designation to its Allocetra therapy for age-related symptomatic knee osteoarthritis in older adults. The RMAT decision cites results from its completed Phase I/IIa trial showing statistically significant improvements in pain and function vs placebo, durable to six months. Enlivex is starting a Phase IIb trial enrolling 182 patients and plans an FDA Type B meeting.